Federal Register / Vol. 87, No. 82 / Thursday, April 28, 2022 / Notices 25285 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Chris Kornak at 240–627–3705 or 

Chris.Kornak@nih.gov. Licensing 

information may be obtained by 

communicating with the Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases, 5601 Fishers Lane, 

Rockville, MD 20852; tel. 301–496– 

2644. A signed Confidential Disclosure 

Agreement will be required to receive 

copies of unpublished information 

related to the invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

Replication-Competent Adenovirus 

Type-4 HIV Env Vaccines and Their 

Use 

Description of Technology: National 

Institute of Allergy and Infectious 

Diseases (NIAID), International AIDS 

Vaccine Initiative (IAVI), Emergent, and 

Scripps have developed two 

recombinant adenovirus type 4 (Ad4) 

vector-based vaccine candidates. These 

replicating Ad4 vector-based candidates 

have shown improved activity against 

tier 2 HIV–1 isolates in experimental 

animals. Tier 2 isolates are among the 

most prevalent in infected populations. 

The two candidates, Ad4-Env150KN 

and Ad4-Env145NFL, incorporate novel 

design features based on Ad4-EnvC150 

(1086c). Specifically, the truncation of 

the cytoplasmic tail of Env increases 

cell surface expression and has resulted 

in improved antigenicity from both 

candidates. 

Additionally, the upper respiratory 

tract administration offers a way to 

bypass pre-existing Ad4 immunity in 

most people. Furthermore, unlike nonreplicating vectors, these vaccines may 

evoke a durable immune response. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications 

• Prophylaxis against HIV–1. 

Competitive Advantages 

• Replicating vector may invoke 

durable immunity against HIV–1. 

• Potential for prophylactic use in 

high-risk populations. 

• Upper-respiratory (intranasal) 

administration will bypass pre-existing 

Ad4 immunity in most people. 

Development Stage 

• Phase 1 Clinical Trial 

(NCT03878121). 

Inventors: Mark Connors (NIAID), Jeff 

Alexander (Emergent), Lo Vang 

(Emergent), Richard Wyatt (Scripps and 

IAVI), and Javier Guenaga (IAVI). 

Publications: Alexander J., Mendy J., 

Vang L., Avanzini J.B., Garduno F., et al. 

(2013) Pre-Clinical Development of a 

Recombinant, Replication-Competent 

Adenovirus Serotype 4 Vector Vaccine 

Expressing HIV–1 Envelope 1086 Clade 

C. PLOS ONE 8(12): e82380. https://

doi.org/10.1371/journal.pone.0082380. 

Intellectual Property: HHS Reference 

No. E–105–2020–0–PCT–01—PCT 

Application No. PCT/US21/45389 filed 

on 10 August 2021. 

Licensing Contact: To license this 

technology, please contact Chris Kornak 

at 240–627–3705 or Chris.Kornak@

nih.gov, and reference E–105–2020. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize this technology. In 

particular, NIAID would be very 

interested in a partnership with an 

entity that has a complementary HIV 

vaccine technology. For collaboration 

opportunities, please contact Chris 

Kornak at 240–627–3705 or 

Chris.Kornak@nih.gov. 

Dated: April 25, 2022. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2022–09158 Filed 4–27–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Secretary; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Interagency Pain 

Research Coordinating Committee. 

The meeting will be open to the 

public via NIH Videocast https://

videocast.nih.gov/. Individuals who 

plan to participate and need special 

assistance, such as sign language 

interpretation or other reasonable 

accommodations, should notify the 

Contact Person listed below in advance 

of the meeting. 

Name of Committee: Interagency Pain 

Research Coordinating Committee. 

Date: June 7, 2022. 

Time: 2:00 p.m. to 5:00 p.m. Eastern 

Daylight Time (EDT). 

Agenda: The meeting will cover committee 

business items and IPRCC member updates. 

Items discussed will include updates on pain 

workforce enhancement, pain research, 

patient engagement, and diversity efforts. 

Webcast Live: https://videocast.nih.gov/. 

Deadline: Submission of intent to submit 

written/electronic statement for comments: 

Tuesday, May 31st, by 5:00 p.m. EDT. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Bethesda, MD 

20892 (Virtual Meeting). 

Contact Person: Linda L. Porter, Ph.D., 

Director, Office of Pain Policy and Planning, 

Office of the Director, National Institute of 

Neurological Disorders and Stroke, NIH, 31 

Center Drive, Room 8A31, Bethesda, MD 

20892, Phone: (301) 451–4460, Email: 

Linda.Porter@nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Visit the IPRCC website for more 

information: https://iprcc.nih.gov. Agenda 

and any additional information for the 

meeting will be posted when available. 

Dated: April 25, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–09140 Filed 4–27–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License, Inter-Institutional AgreementInstitution Lead: Engineered Influenza 

Neuraminidase Antigens 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Institute of 

Allergy and Infectious Diseases (NIAID), 

an institute of the National Institutes of 

Health (NIH), Department of Health and 

Human Services (HHS), is 

contemplating the grant of an exclusive, 

sublicensable patent license to the 

University of Washington, located in 

Seattle, State of Washington, U.S.A. in 

its rights to the inventions and the 

patent applications listed in the 

SUPPLEMENTARY INFORMATION section of 

this notice. 

DATES: Only written comments and/or 

applications for a license which are 


jspears on DSK121TN23PROD with NOTICES1